Pfizer Inc. (NYSE:PFE) Evercore ISI HealthCONx Conference Call November 29, 2018 8:45 AM ET
Executives
Chuck Triano - SVP IR
Chris Boshoff - SVP & Head of Immuno-Oncology
Analysts
Umer Raffat - Evercore ISI
Umer Raffat
Excellent. Well, a pleasure to have Pfizer Management join us. We have Chris and Chuck joining us from Pfizer. Before we begin, may I'll turn over to Chuck to introduce.
Chuck Triano
Chris Boshoff and he is among other things. Very involved with our Immuno-Oncology Division, part of Pfizer Oncology. So Chris has a vast scientific background. Very clinical trials, design, all good things like that and then for myself, I run the Investor Relations group at the company. Again, thanks for having us and happy to be here. Look forward to conversation.
Umer Raffat
Excellent. Well, if you don't mind, Chuck, we might start with a few corporate strategy and high level questions with you before we dig into some of the more R&D stuff.
The first one being and this is something I've mentioned as a potential risk factor to the states which was when you guys announced your price increases in July and then some tweaks happen and you rolled it back, there was a lot of feedback shared on the street that there may have been conversations between the President and Pfizer's CEO on potentially doing something about a rebate or else the increases will be back on. We're now seeing that state of California has been notified by this take in price increases in January.
So my question is this. Is the administration aware of that and should we be expecting any tweets like how should we anticipate that going into January? That first week is already stressful as it is.
